Equities

Tonghua Dongbao Pharmaceutical Co Ltd

600867:SHH

Tonghua Dongbao Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)7.07
  • Today's Change-0.13 / -1.81%
  • Shares traded9.59m
  • 1 Year change-32.92%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy3
Outperform3
Hold1
Sell0
Strong Sell0

Share price forecast in CNY

The 6 analysts offering 12 month price targets for Tonghua Dongbao Pharmaceutical Co Ltd have a median target of 12.71, with a high estimate of 14.08 and a low estimate of 9.00. The median estimate represents a 79.77% increase from the last price of 7.07.
High99.2%14.08
Med79.8%12.71
Low27.3%9.00

Dividends in CNY

In 2023, Tonghua Dongbao Pharmaceutical Co Ltd reported a dividend of 0.25 CNY, which represents a 50.00% decrease from last year. The 4 analysts covering the company expect dividends of 0.16 CNY for the upcoming fiscal year, a decrease of 38.00%.
Div growth (TTM)-50.00%
More ▼

Earnings history & estimates in CNY

On Aug 30, 2024, Tonghua Dongbao Pharmaceutical Co Ltd reported 2nd quarter 2024 losses of -0.23 per share.
The next earnings announcement is expected on Jan 31, 2025.
Average growth rate+9.88%
Tonghua Dongbao Pharmaceutical Co Ltd reported annual 2023 earnings of 0.590 per share on Jan 29, 2024.
Average growth rate+13.06%
More ▼

Revenue history & estimates in CNY

Tonghua Dongbao Pharmaceutical Co., Ltd. had 2nd quarter 2024 revenues of 148.63m. This missed the 164.67m estimate of the one analyst following the company. This was 77.66% below the prior year's 2nd quarter results.
Average growth rate-18.53%
Tonghua Dongbao Pharmaceutical Co., Ltd. had revenues for the full year 2023 of 3.08bn. This was 10.69% above the prior year's results.
Average growth rate+3.21%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.